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Implications of COVID-19 in high burden
countries for HIV/TB: A systematic review of
evidence
Jacques L. Tamuzi1, Birhanu T. Ayele1, Constance S. Shumba2,3, Olatunji O. Adetokunboh1,4,
Jeannine Uwimana-Nicol5, Zelalem T. Haile6, Joseph Inugu7 and Peter S. Nyasulu1,8*

Abstract
Background: The triple burden of COVID-19, tuberculosis and human immunodeficiency virus is one of the major
global health challenges of the twenty-first century. In high burden HIV/TB countries, the spread of COVID-19
among people living with HIV is a well-founded concern. A thorough understanding of HIV/TB and COVID-19
pandemics is important as the three diseases interact. This may clarify HIV/TB/COVID-19 as a newly related field.
However, several gaps remain in the knowledge of the burden of COVID-19 on patients with TB and HIV. This study
was conducted to review different studies on SARS-CoV, MERS-CoV or COVID-19 associated with HIV/TB co-infection
or only TB, to understand the interactions between HIV, TB and COVID-19 and its implications on the burden of the
COVID-19 among HIV/TB co-infected or TB patients, screening algorithm and clinical management.
Methods: We conducted an electronic search of potentially eligible studies published in English in the Cochrane
Controlled Register of Trials, PubMed, Medrxiv, Google scholar and Clinical Trials Registry databases. We included
case studies, case series and observational studies published between January, 2002 and July, 2020 in which SARSCoV, MERS-CoV and COVID-19 co-infected to HIV/TB or TB in adults. We screened titles, abstracts and full articles for
eligibility. Descriptive and meta-analysis were done and results have been presented in graphs and tables.
Results: After removing 95 duplicates, 58 out of 437 articles were assessed for eligibility, of which 14 studies were
included for descriptive analysis and seven studies were included in the meta-analysis. Compared to the descriptive
analysis, the meta-analysis showed strong evidence that current TB exposure was high-risk COVID-19 group (OR
1.67, 95% CI 1.06–2.65, P = 0.03). The pooled of COVID-19/TB severity rate increased from OR 4.50 (95% CI 1.12–
18.10, P = 0.03), the recovery rate was high among COVID-19 compared to COVID-19/TB irrespective of HIV status
(OR 2.23, 95% CI 1.83–2.74, P < 0.001) and the mortality was reduced among non-TB group (P < 0.001).
Conclusion: In summary, TB was a risk factor for COVID-19 both in terms of severity and mortality irrespective of
HIV status. Structured diagnostic algorithms and clinical management are suggested to improve COVID-19/HIV/TB
or COVID-19/TB co-infections outcomes.
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Background
The triple burden of COVID-19, tuberculosis (TB) and
human immunodeficiency virus (HIV) is one of the
major and persistent global health challenges of the
twenty-first century. In the last two decades, three major
coronavirus epidemics have been reported worldwide.
Those epidemics are caused by different agents: severe
acute respiratory syndrome coronavirus (SARS-CoV) in
2002, Middle East respiratory syndrome coronavirus
(MERS-CoV) in 2012 and the current of SARS-CoV-2
outbreak, known as COVID-19 [1]. In 2002, SARS-CoV
originated in Guangdong province, China, spreading to
37 countries, and the subsequent global epidemic was
associated with 8096 cases and 774 deaths [2]. Ten years
later, the MERS-CoV spread to 27 countries, causing
2494 infected cases and 858 deaths worldwide [2, 3].
The novel coronavirus currently known as (2019-nCoV)
was identified in 2019 and is the third highly pathogenic
CoV detected, with a fatality rate varying across countries and ranges of age. In addition, the 2019-nCoV
transmissibility is higher, the 2019-nCoV mean R0 (R0 is
used to measure virus transmissibility) ranged from 3.3
to 5.5, and it appeared higher than that of SARS-CoV
(2–5) and MERS-CoV (2.7–3.9) [2–6]. An estimated 18,
142,718 people have been infected and 691,013 have
died from December 2019 to 04 August 2020, yielding a
fatality rate of 3.81% % worldwide [7].
HIV, TB and newly Emerging Infectious Diseases such
as Coronavirus epidemics are expected to overlap in
high HIV and TB burden countries. The intersecting
coronavirus, HIV and TB epidemics in countries with a
high burden of HIV and TB infections pose several public health challenges. In fact, TB is the leading immunesuppressing infection and the most common cause of
death among HIV-infected patients [8]. Worldwide,
there were 37.9 million [32.7 million–44.0 million]
people living with HIV and 1.7 million [1.4 million–2.3
million] people became newly infected with HIV at the
end of 2018 [9]. WHO reports that people living with
HIV are 20 times more likely to develop TB than their
counterparts [10]. It is estimated that 1.1 million people
worldwide live with TB and HIV, 80% of whom live in
sub-Saharan Africa [11]. Since the emergence of HIV,
TB incidence is increasing and causing a high mortality
rate among people living with HIV/AIDS over the last
ten years [12]. In the post-mortem, the overall prevalence of TB in adults and children was huge and
accounted for almost 40% of HIV-related facility-based
deaths in adults in resource-limited countries [13]. This
is greater than the WHO/UNAIDS estimate that overall
TB accounts for approximately 25% of HIV/AIDS related deaths worldwide [13]. How COVID-19 will manifest itself in persons co-infected with HIV/TB is still
uncertain [14]. Populations infected with HIV and TB,
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those with undiagnosed pulmonary TB (PTB), drugresistant tuberculosis or complex presentations such as
disseminated types and those who have only started PTB
treatment may be at elevated risk for severe responses if
they are infected with COVID-19 [14]. In the future,
lung lesions associated with COVID-19 may increase the
risk of PTB, which induces a true vicious circle of HIVTB-COVID-19 co-infection. TB incidence is also anticipated to increase in high burden HIV/TB countries
including sub-Saharan countries with high COVID-19
burden. While COVID-19 continues to spread across
the world, many areas face the risk of infection with
SARS-CoV-2 and the obstacles and challenges to sustaining the continuum of HIV and TB treatment in
high-burden HIV/TB countries are increasing [14]. Coinfection SARS-CoV/HIV/TB was previously not a major
threats because SARS-CoV and MERS-CoV pandemics
did not occur in countries with high HIV/TB burden.
Since December 2019, COVID-19 is spreading very fast,
with the high HIV/TB burden countries not spared from
the pandemic and the number of new COVID-19 cases
is expected to rise in the next few months. The intersecting coronavirus, TB and HIV epidemics in subSaharan African countries where HIV and TB have the
highest prevalence and incidence respectively, pose
many challenges from the point of view of COVID-19/
TB diagnostics, COVID-19/HIV/TB clinical management and post COVID-19 epidemic TB incidence as
COVID-19 pulmonary fibrosis may rapidly increase TB
incidence [15].
In fact, the pathogenicity of COVID-19 could be accelerated in people living with HIV who have compromised
immunity [1]. Recent evidence has indicated a substantial association between coronavirus-related Lower Respiratory Tract Infections (LRTIs) and increased risk of
death in immune-compromised individuals [16, 17]. At
the same time, the depletion of CD4 T cells in HIV and
latent TB-infection disrupts the integrity and architecture of TB granulomas in the lung, thus facilitating progression to active TB [18–20]. Similarly, TB promotes a
microenvironment that facilitates the replication of HIV1 via various mediators [21]. In fact, irreversible improvements in lung architecture after SARS-CoV and/or
TB play a significant role in both SARS-CoV and TB
pathogenesis. Nonetheless, severe SARS-CoV can induce
the development of rapid pulmonary fibrosis compared
with mild courses of SARS-CoV disease usually advanced to organize phase diffuse alveolar damage (DAD)
and eventual long-term deposition of fibrous tissue [15].
On the whole, SARS-CoV, HIV and TB co-infection
may have deleterious consequences in all stages of SARS,
HIV and TB because the triple pandemics are related in
the immuno-pathological phase, constituting a vicious
circle. A thorough understanding of the interactions
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between the three deadly pandemics is crucial. Reviewing the statistics in relation to high burden HIV/TB
countries and recent World Health Organization data
on COVID-19 in Sub-Saharan Africa; the following
countries may expect an increased number of TB during
or post COVID-19: South Africa, Nigeria, Cameroon,
Kenya, Tanzania, Mozambique, Zambia, Zimbabwe and
Uganda. The distribution of estimated new HIV cases
(2018), new TB cases and relapses (2018) and COVID19 cases (04 August 2020) are respectively 240,000; 227,
999; 516,882 (South Africa), 130,000; 103,921; 44,129
(Nigeria), 23,000; 23,403; 17,718 (Cameroon), 46,000; 94,
534; 22,597 (Kenya), 72,000; 74,692; 509 (Tanzania), 150,
000; 92,381; 1973 (Mozambique), 48,000; 35,071; 6580
(Zambia), 38,000; 25,204; 4075 (Zimbabwe) and 53,000;
55,835; 1195(Uganda) [7, 10, 22]. The map was drawn to
illustrate the distribution of COVID-19, HIV and TB in
the nine high burden countries in Sub-Saharan African
(Fig. 1). The aim of this study was to review different
studies on SARS-CoV or MERS-CoV associated with
HIV/TB co-infection or TB only and understands the interactions between HIV, TB and COVID-19 and its implications on the burden of the COVID-19 among TB/
HIV patients, screening algorithm and management.

Methods
The protocol was accepted by the international prospective register of systematic reviews (PROSPERO)
(identification number: CRD42020181457). We conducted a systematic review of the literature to examine
SARS-CoV or MERS-CoV associated with HIV/TB or
TB co-infection. As we anticipated heterogeneity in the
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literature, meta-analysis and descriptive analysis were
undertaken. Meta-analysis was based on random-effects
modeling using Review Manager 5.3 [23] and MetaEssentials [24] was also used to compute Egger’s regression and Begg and Mazumdar rank correlation test to
evaluate possible publication bias. The odds ratio (OR)
for COVID-19/HIV co-infection or COVID-19 in relation to TB exposure was used as the summary measure
of risk in these meta-analyses. Heterogeneity across included studies was estimated by χ2 and I2. Forest plots
and relevant supporting statistics were examined. Metaanalyses for subgroups (on the basis of COVID-19/HIV/
TB vs COVID-19/TB) were also undertaken to investigate heterogeneity between the subsets. We also computed the test of two proportions with STATA version
14 to compare SARS, MERS or COVID-19 disease severity compared to TB and/or HIV in descriptive analysis.
We utilized formal methods of literature search, selection of articles for inclusion, an abstraction of data and
quality assessment, and synthesis of results to review the
literature on to examine SARS-CoV or MERS-CoV or
COVID-19 associated with HIV/TB or TB co-infection.
Inclusion criteria

The inclusion criteria were studies published in English,
from January 2020 until July 2020 that established cooccurrence of SARS-CoV, MERS-CoV, COVID-19 HIV
and TB. Study designs included case reports, case series
and observational studies (case-control, prospective and
retrospective cohorts). Studies reporting COVID-19/HIV
co-infection without screening PTB, those reporting
other outcomes, letters to the editor, theoretical and

Fig. 1 Distribution of COVID-19, HIV and TB in the nine high burden countries in Sub-Saharan African
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incomplete studies were excluded. The outcomes include TB occurrence (before, during or after SARS,
MERS or COVID-19), SARS, MERS or COVID-19 severity (mild, moderate, severe and critical stages) in case of
HIV/TB or TB co-infections, the mean time of COVID19 severe/critical stages occurrence and the recovery and
mortality rates.
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(NOS) [25]. The Newcastle-Ottawa scale assessed the selection, comparability and exposure of a case-control
study and selection, comparability, and outcome of a cohort study. Nine stars reflect maximum ranking, and the
sample with over 6 stars was considered to be of reasonably high quality. Any questions about the content of
the included studies were determined in consultation
with another reviewer (PSN).

Search strategy

We searched eligible studies from 01 January 2002 to 27
July 2020 through Medline (PubMed), Google Scholar,
Medrxiv and the Cochrane Library without any study
design, published in English. Additionally, the WHO
COVID-19 database [22] and Clinicaltrials.gov were also
used to search for ongoing and completed studies related to co-infection COVID-19/HIV/TB. The following
terms were used “SARS-CoV”, “MERS-CoV”, “COVID19”, “SARS-CoV-2” AND “pulmonary tuberculosis”,
“PTB”, “lung TB”, “TB” AND “HIV/TB co-infection”
AND “TB/SARS co-infection” AND “TB/MERS coinfection” “TB/Covid-19 co-infection” AND “HIV/SARS
co-infection” AND “HIV/MERS co-infection” AND
“HIV/COVID-19 co-infection”. Relevant articles published in English that resulted from the searches, and
references cited therein, were reviewed and duplicate
studies were removed. After removing duplicates, we
checked the title and abstract and reviewed full-text, inclusions and exclusions were recorded following PRIS
MA guidelines presented in the form of a PRISMA flow
diagram and detailed reasons recorded for exclusion.
Critical appraisal checklists appropriate to each study
design were applied and conducted in pairs (JTL and
PSN).

Results
Search results

A customized data extraction form was designed and
piloted prior to data extraction. For each study included,
we collected the following information: authors and publication year, title and journal, study country, study design, sample size, participants characteristics such as age
and sex, the number of conditions included (SARS-CoV,
MERS-CoV, COVID-19, HIV and TB) and the outcomes
include TB occurrence (before, during or after SARS,
MERS or COVID-19), SARS, MERS or COVID-19 severity (mild, moderate, severe and critical stages) in case of
HIV/TB or TB co-infections, the average time of
COVID-19 severe/critical stages occurrence, and the recovery and mortality rates. The data extraction was conducted in pair by (JLT and BTA). Conflict resolution
was conducted by a third co-author (PSN).

Electronic search identified 532 articles. Inclusions and
exclusions were reported following PRISMA guidelines
presented in the form of a PRISMA flow diagram (Fig. 2)
with reasons for exclusion recorded (Table 1) as follows:
95 duplicates were removed; after reading the titles of
articles, 379 articles were removed. Among 58 records
screened, 21 full-text studies were assessed for eligibility.
Thirty-seven articles were excluded because there were
either incomplete or irrelevant articles. Twenty-one
studies were included for qualitative analysis, of which
five were case reports, eight case series, one case-control
and seven cohort studies (Table 2). Seven out of eight
observational studies were included in the meta-analysis.
One retrospective cohort was included in the descriptive
analysis because COVID-19/TB co-infected cases were
identified in both cases and exposed groups [47]. Each
article that met selection criteria was fundamentally
assessed for Author/Country, Population/Study design,
Exposures, Comparators, Treatments, TB occurrence
and SARS/MERS/COVID-19 severity, recovery and mortality rate.
Table 2 presents a summary of 21 included studies.
The review included 28,387 COVID-19, 6 SARS-CoV
and 2 MERS-CoV participants with HIV/TB or TB.
Among them, 1294 were COVID-19/TB, 1094 COVID19/HIV/TB, 5 SARS-CoV/TB, 2 MERS-CoV/TB and 1
SARS-CoV/HIV/TB. Four cohort studies [41, 44, 45, 48],
one case control study [38] and four case series [28, 29,
34, 49] were conducted in China, two case series [30, 39]
were done in Singapore, one case series [32] and one
case control study [37] were undertaken in Saudi Arabia,
a case series [40] was conducted in Italy, one cohort
study was done in South Africa [42] and another in the
Philippines [43], one case study was conducted in the
United State of America [35], other three case studies
were found in Turkey [36], Hong Kong [31] and India
[33] respectively. Lastly, a retrospective cohort was
undertaken in eight countries (Italy, Belgium, Brazil,
France, Russia, Singapore, Spain, and Switzerland) [47].

Assessment of study quality

Quality assessment of included studies

Two reviewers (JTL and BTA) independently assessed
study quality based on the Newcastle-Ottawa scale

The methodological validity of included studies for determining the consistency of case-control study and

Data extraction
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Fig. 2 Flow diagram of SARS-CoV or MERS-CoV or COVID-19 associated with TB/HIV or TB studies included in the review. Note. From
PRISMA: www.prisma-statement.org

cohort studies in meta-analyses was based on the NOS
[25]. This method explores three major components:
range, comparability and exposure. The NOS uses a star
chart with ratings from 0 to 9 for case–control and cohort studies. Since the requirements for a study’s high or
low quality are not well known, we considered a study
with a higher score than the six of each form of study to
be a high-quality study. Among included studies, two
scored seven and high, three scored six and the other
two studies scored less than six and were therefore considered low quality. The NOS scores for the included
studies are shown in Table 1 (Supplementary material).
Descriptive analysis

Fourteen studies (one observational study, eight case
series and five case studies) were included in the descriptive analysis. We identified 113 cases with SARSCoV, MERS-CoV or COVID-19 associated to HIV/TB
or TB. The computed median age between case studies
and case series was 32 years compared to the cohort
study median age of 70 years [47]. Males had higher
SARS-CoV or MERS-CoV or COVID-19 associated to

HIV/TB or TB co-infections than females with 70% (28/
40). Table 2 describes all cases. For further clarifications,
cases were grouped as follows:
Cases of SARS-CoV, MERS-CoV or COVID-19 with previous
history of PTB diagnosis

Six studies (an observational study, four case series and
one case study) [29, 32, 34, 37, 47, 49] included cases
known to have a history of PTB (sputum smear–negative
for acid-fast bacilli) and became infected with SARSCoV (two cases) or MERS-CoV (two cases) or COVID19 (eight cases). PTB diagnosis was made based on previous exposure to TB, relevant symptoms of typical PTB,
chest radiographs suggestive of active disease or IGRA
(Interferon Gamma Release Assay). SARS-CoV or
MERS-CoV was confirmed based on amplification of
SARS-CoV/MERS-CoV RNA by reverse transcriptase–
polymerase chain reaction (RT-PCR) from sputum.
SARS-CoV/TB co-infected cases were managed with
corticosteroids and anti TB drugs. Clinical management
was not specified for MERS-CoV/TB co-infected cases;
however anti TB drugs were administered. Lopinavir/r,
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Table 1 Description of studies excluded in review
N

Author/Country

Population/Study design

Reasons for exclusion

1

Shalhoub 2015
Saudi Arabia

A patient with MERS-CoV/HIV co-infection/case study

TB status was not reported

2

Bogorodckaya 2020
Russia

three TB patients co-infected with COVID-19/ case study

Cases were incompletely reported.

3

Wang 2020
China [26]

A patient with COVID-19/HIV co-infection/case report

TB status was not reported

4

Zhu 2020
China

A patient with COVID-19/HIV co-infection/case report

TB status was not reported

5

Zhao 2020
China

A patient with COVID-19/HIV/HCV co-infection/ case report

TB status was not reported

6

Baluku 2020
Uganda

A patient with COVID-19/HIV co-infection /case report

TB status was not reported

7

Blanco 2020
Spain

Five cases of COVID-19/HIV co-infection/ clinical case series

None reported TB status

8

Riva 2020
Italy

Three cases with COVID-19/HIV co-infection / case series

None reported TB status

9

Aydin 2020
Turkey

Three patients with COVID-19/HIV co-infection /case series

Outcomes of interest were not reported

10

Benkovic 2020
USA

Four patients with COVID-19/HIV Co-infection/Case series

Outcomes of interest were not reported

11

Haddad 2020
USA

A case with COVID-19/HIV co-infection/Case report

TB screening was not reported

12

Gervasoni 2020
Italy

47 COVID-19/HIV co-infected patients Retrospective study

Outcomes of interest were not reported

13

Wang 2020
China [26]

A patient with COVID-19/HIV Co-infection/Case report

TB status was not reported

14

Härter 2020
Germany

33 COVID-19/HIV co-infected patients Retrospective study

Outcomes of interest were not reported

15

Wu 2020
China

Two patients with COVID-19/HIV co-infection/Case series

TB screening was not reported

16

Del 2020
Spain [27]

77,590 COVID/HIV co-infected cases

Outcomes of interest were not reported

17

Bulled 2020
South Africa

Comment on COVID-19/HIV/TB co-infection

This was a commentary

18

Tadolini 2020
Italy

49 patients with COVID-19/TB co-infection

Duplicate report from the same cohort

19

Chen 2020
China [28]

COVID-19/TB burden

Letter to the editor without case report

20

Drain 2020
USA

Explanatory article on COVID/HIV burden

TB screening was not reported

21

Karim 2020
USA

Included percentage of COVID-19/HIV/TB report

No primary data reported

22

Pang 2020
China

Included COVID-19/TB cases

A correspondence

23

Wang 2020
China [26]

A case of COVID-19/HIV co-infection

The outcomes of interest were not reported

24

Kilds 2020
USA

A case of COVID-19/HIV co-infection

The outcomes of interest were not reported

25

Ridgway 2020
USA

A case series of five COVID-19/HIV co-infection

Had no outcome of interest reported

26

Sigel 2020
USA

Eighty eight COVID-19/HIV co-infection

Had no outcome of interest reported

27

Patel 2020
USA

A case study of COVID-19/HIV co-infection

The interest outcome was not reported
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Table 1 Description of studies excluded in review (Continued)
N

Author/Country

Population/Study design

Reasons for exclusion

28

Guo 2020
China

A survey among COVID-19/HIV co-infected cases

The interest outcome was not reported

29

Shalev 2020
USA

31 patients with COVID-19/HIV co-infection

The outcomes of interest were not reported

30

Karmen-Tuohy 2020
USA

A case control of 21 patients COVID-19/HIV co-infection

The outcomes of interest were not reported

31

Toombs 2020
United Kingdom

Three Cases with COVID-19/HIV co-infection

Do not contain the outcome of interest

32

Ruan 2020
China

Three cases with COVID-19/HIV co-infection

Had no outcome of interest reported

33

Sun 2020
Singapore

A case of SARS-2/HIV co-infection

Had no outcome of interest reported

34

Richardson 2020
USA

43 cases of SARS-2/HIV co-infection

Do not contain the outcome of interest

35

Ho 2020
USA

93 cases of SARS-s/HIV co-infection

The outcomes of interest were not reported

36

Su 2020
China

Two cases with SARS-2/AIDS co-infection

The outcomes of interest were not reported

37

Kumar
India

A case of COVID-19/HIV co-infection

Had no outcome of interest reported

Arbidol, Ribavirin, corticoids (dexamethasone and methyl prednisolone), prophylactic anticoagulation, empirical antibiotics, traditional Chinese medicine and antiTB drugs were indicated to COVID-19/TB co-infected
cases. Eight out of fourteen had severe/critical disease
course among which one case of SARS-CoV, one of
MERS-CoV and six cases of COVID-19 and had a long
recovery process.
SARS-CoV or COVID-19 cases with PTB co-infection

Seven studies (an observational study, two case series
and four case studies) [29, 31, 33, 35, 36, 47, 49] diagnosed PTB (positive acid-fast bacilli smear on sputum
samples or IGRA), while cases were admitted for SARSCoV (two cases) and COVID-19 (twelve cases). SARSCoV and COVID-19 were confirmed by RT-PCR, and
microscopy as well as medical imaging diagnosed TB. A
case of SARS-CoV/HIV/TB co-infection [31] was managed with abacavir/efavirenz/kaletra/tenofovir/ribavirin,
prednisolone and anti TB drugs and another case with
SARS-CoV/TB co-infection [29] was managed with
mechanical ventilation, corticosteroids and anti TB
drugs. All COVID-19/TB co-infected cases were managed in the same way as for previous PTB/COVID-19
cases.
Cases of PTB with history of SARS-CoV

Two cases were diagnosed with PTB with positive bacilli
smear respectively four and two months after SARSCoV [30]. At day 80 of disease on convalescence, one of
the cases was positive for coronavirus IgG serum

antibody and the other case was positive for SARS coronavirus by PCR of an endotracheal tube test, as well as
coronavirus IgM and IgG antibodies in the blood. Both
of them had severe COVID-19 before developing PTB.
Intravenous immunoglobulin and a short course of highdose corticosteroids were indicated during the SARS
course and anti TB drugs were administered during the
TB course. The said patients remained clinically stable
at follow-up.
Cases were stratified by PTB diagnosis. 41.36% (12/29)
of cases of SARS-CoV, MERS-CoV or COVID-19 had
previous history of PTB diagnosis. 74% of SARS-CoV or
COVID-19 Cases had PTB co-infection, and 6.89% (2/
29) of PTB had a history of SARS-CoV. The test of two
proportions between ‘severe/critical SARS, MERS and
COVID-19 cases with HIV/TB or TB co-infection 53%
(20/38)’ versus ‘mild/moderate SARS, MERS and
COVID-19 cases with HIV/TB or TB co-infection 47%
(18/38)’ was not statistically significant (P = 0. 6009).
The onset of COVID-19 severe/critical stages was mean
of 3.4 days [38] and a median of 9 days [47] for two observational studies and 10 days for a case series [34].
Three studies [28, 30, 32, 37, 39, 40, 47] reported the recovery and mortality rate among SARS, MERS and
COVID-19 cases with HIV/TB or TB co-infection which
were respectively 90.26% (102/113) and 9.74% (11/113).
The mortality rate of 9.74% among COVID-19/TB or
COVID/HIV/TB co-infected patients should be considered with caution because of poor study design and
small sample size. However, the mortality rates for
COVID-19/TB or COVID/HIV/TB co-infection seem to

PTB
SARS-CoV

-Two males of 54 and 39 years old PTB
with confirmed SARS-CoV
SARS-CoV
-Case series

HIV
Latent TB
SARS-CoV

PTB
MERS-CoV

PTB
COVID-19

Previous TB PTB
COVID-19

-Three males of 48(case 1), 18
(case 2) and 20 years (case 3) old
with confirmed SARS-CoV
-case series

-30 years old male with confirmed
SARS-CoV and HIV on ART
-Case report

All three patients were males with
26, 67 and 76 years
-Case series

61-year-old male with confirmed
COVID-19 and history of Parkinson’s disease.
Case study

55-year-old male with a history of
myelodysplastic
Syndrome, immunocompromised,
kidney failure and confirmed with
COVID-19
Case study

Low 2004
Singapore [30]

Wong 2004
Hong Kong [31]

Alfaraj 2017
−13-year-old girl and A 30-yearKingdom of
old female with confirmed MERSSaudi Arabia [32] CoV
-Case series

76-year- old female with
confirmed COVID-19
Case study

Liu 2006
China [29]

Singh 2020
India [33]

He 2020
China [34]

Cutler 2020
USA [35]

Çınar 2020
Turkey [36]
Disseminated TB
COVID-19

PTB
COVID-19

Exposures

Author/Country Population/Study design

Table 2 Description of studies included in review

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

Comparators

COVID-19
convalescent plasma
Favipiravir
meropenem
Ventilatory support
Anti-TB drugs

Hydroxychloroquine
Oxygen
supplementation
Anti-TB drugs

Lopinavir + Ritonavir
Arbidol
Methyl prednisolone
Antibiotics
Traditional Chinese
medicine
Intravenous
immunoglobulin
Ventilatory support
Antituberculosis

hydroxychloroquine
400 mg twice daily in
addition to antibiotics.
Anti TB drugs

intensive care
admission
Anti TB drugs

Abacavir 300 mg
Efavirenz 600 mg
Kaletra Tenofovir 300
mg
Ribavirin 1200 mg
prednisolone 25 mg

intravenous
immunoglobulin
short course of highdose corticosteroids
Anti TB drugs

Corticosteroids
mechanical ventilation
Anti TB drugs

Treatments

Mild to moderate COVID19

The 13 years old had
severe MERS-CoV. However, the disease severity
was moderate with the
30 years old.

Mild course SARS

Both of them developed
severe SARS-CoV

Two patients developed
mild SARS-CoV and one
developed severe stage.

The patient
recovered from
COVID-19

Both of the
cases recovered
from MERS-CoV

The case
recovered from
SARS-CoV

Both of the
cases recovered
from SARS-CoV

All of them
recovered form
SARS-CoV and
continue anti-TB
drugs

SARS-CoV/MERS/COVID- SARS-CoV/
19 Severity rate/Time
MERS-CoV/
COVID-19
Recovery rate/
Time

TB diagnosed in
hospitalization

TB diagnosed in
hospitalization

Critical COVID-19 stage

Critical COVID-19 stage

Recovered for
COVID-19

Recovered for
COVID-19

Past medical history of All of them had severe
All of the three
TB years ago for all
type of COVID-19
cases recovered
the three patients
10 days after onset for the from COVID-19
first symptom

Diagnosed with TB
during admission

Both patients initially
had TB before MERSCoV

Diagnosed with PTB
during hospitalization

PTB developed after
four and 2 months
prior to SARS-CoV.

PTB diagnosed while
case 1 was in the
hospital. Case 2 and 3
were known TB on
treatment.

TB occurrence

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

Mortality
rate

Tamuzi et al. BMC Infectious Diseases
(2020) 20:744
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PTB
COVID-19

PTB
COVID-19

Faqihi 2020
60 year-old male, hypertensive
Saudi Arabia [37] and diabetic, with confirmed
COVID-19
Case study

48 year-old, 26-year-old and 46year-old males with confirmed
COVID-19/TB co-infection
Case series

32-year-old, 33-year-old, 22-year
old and 40-year old males COVID19/TB co-infected patients
Case series

20 confirmed cases of COVID-19/
PTB
TB co-infection. Among them, one Disseminated TB
case was also HIV-infected. The
COVID-19
median age was 39 years
Case series

Only four cases of COVID-19/TB
PTB
co-infection were included in a
COVID-19
cohort of 203 confirmed COVID-19
cases.
Case series

8 confirmed cases of COVID-19/TB
prospective cohort study

3978 COVID-19/HIV co-infected
patients
18,330 COVID-19 infected patients,
public sector patients aged ≥20
years.
Population prospective cohort
study

Liu 2020a
China [38]

Tham 2020
Singapore [39]

Stochino 2020
Italy [40]

Chen 2020
China [28]

Du 2020
China [41]

Davies 2020
South Africa [42]

Survivors vs deceased

COVID-19/HIV/TB vs
COVID-19/TB

Previous TB status
Latent TB
HIV
COVID-19

Survivors vs deceased

N/A

N/A

N/A

N/A

Comparators

PTB
COVID-19

PTB
COVID-19

Exposures

Author/Country Population/Study design

Table 2 Description of studies included in review (Continued)

Antiretroviral therapy
Anti-TB
COVID-19 antiviral
therapies

N/A

N/A

Hydroxychloroquine.
Ventilatory support
Anti-TB drugs

COVID-19 antiviral
drugs
Anti-TB drugs

Arbidol
Moxifloxacin
Linezolid
immunomodulatory
therapy with
thymopentin
Ventilatory support
Anti-TB drugs

Lopinavir/ritonavir
Ribavirin
Dexamethasone
Prophylactic
anticoagulation
Supportive ICU care
Anti-TB drugs

Treatments

Critical COVID-19 stage

COVID-19/HIV/TB
current TB: 172/3863
Previous TB: 864/3863
COVID-19/TB
current TB: 145/ 17,
820
Previous TB: 10/510

N/A

N/A

N/A

N/A

N/A

N/A

N/A

7 out of 20 developed
severe/critical COVID-19
13 out of 20 developed
mild/moderate COVID-19
Average of 32 [range 14–
57] days

N/A

COVID-19/HIV/
TB: 1039/1094
COVID-19: 2827/
2884
COVID-19/TB:
979/1034
COVID-19:
16841/17296

N/A

N/A

19 out of 20
patients
recovered.

All of them
recovered.

All of them
recovered from
COVID-19 with
the range of 9
to 14 days

Recovered for
COVID-19 after
20 days

SARS-CoV/MERS/COVID- SARS-CoV/
19 Severity rate/Time
MERS-CoV/
COVID-19
Recovery rate/
Time

The first and the last
All of them developed
case had LTBI and the severe/critical COVID-19
second was a previous courses
MDR-TB

Previous TB history

TB occurrence

COVID-19/
HIV/TB
Current TB:
16/172
Previous
TB: 42/864
COVID-19/
TB
Current TB:
10/145
Previous
TB: 45/834

COVID-19/
TB: 0/8
COVID-19:
21/171

1 case out
of 4 died.

1 patient
died.

N/A

N/A

N/A

Mortality
rate

Tamuzi et al. BMC Infectious Diseases
(2020) 20:744
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1350 confirmed cases of COVID-19 PTB
among which 8 were COVID-19/
COVID-19
TB co-infected cases.
Age (44.1 ± 17.9) years
Retrospective cohort study

Zhang 2020b
China [44]

Previous TB status
Latent TB
COVID-19
One patient with
HIV

Non-severe vs Severe
COVID-19

−140 confirmed COVID-19 cases, 2 PTB
of whom had secondary PTB
COVID-19
-Retrospective study

Zhang 2020
China [44]

20 confirmed COVID-19/
TB cases
Retrospective cohort
study (Cohort B)

Non-severe vs Severe
COVID-19

Hydroxychloroquine
Lopinavir/ ritonavir
Azythromycin
Empiric antibiotic
Enoxaparine 4000 IU
Dexamethasone
Oxygen through nonrebreather, 15lt/min
Anti TB drugs

N/A

N/A

N/A

COVID-19/TB
Recovered: 57
/106
COVID-19
Recovered: 302/
424

N/A

60 cases
recovered from
COVID-19/TB coinfection the
both cohorts.

−5 patients had severe
COVID-19
− 8 patients developed
critical COVID-19
-Critical COVID-19: median
of 9 (range 6–14) days
after
COVID-19 diagnosis
−3 with previous TB
diagnosed
−8 (simultaneous
diagnosis of COVID-10
and TB
−11 had COVID-19 diagnosed between 7
and 75 days) after the
TB diagnosis

N/A

N/A

Severe: 3/229
Not severe: 2/1121

Severity COVID-19/TB Severe: 2/58
Not severe: 0/82

Severe: 4/269
Not severe: 5/ 279

Severity:
N/A
Mild/Moderate:
0/27
Severe/Critical: 3/9
-severe/critical COVID-19:
3.4 days after initial symptom development.

Admitted in the hospital
COVID-19/TB: 67/106
COVID-19: 236/424

SARS-CoV/MERS/COVID- SARS-CoV/
19 Severity rate/Time
MERS-CoV/
COVID-19
Recovery rate/
Time

N/A

N/A

N/A

Previous TB: 8/13
Current TB: 3/13

N/A

TB occurrence

9 out of 69
died from
COVID-19/
TB coinfection

N/A

N/A

N/A

N/A

COVID-19/
TB
Died: 25
/106
COVID-19
Died: 46/
424

COVID-19/
HIV/TB: 58/
1034
COVID-19/
HIV: 57/
2884
COVID-19/
TB: 55/1034
COVID-19:
455/17296

Mortality
rate

(2020) 20:744

Motta 2020
- 49 confirmed TB and COVID-19
Italy, Belgium,
cases, median age 70 years
Brazil, France,
Retrospective cohort study
Russia,
Singapore, Spain,
Switzerland [47]

Non-Severe vs severe
COVID-19

PTB
COVID-19

A total of 549 patients with
COVID-19 were enrolled. The median age of study population was
60 years.
Retrospective study

Li 2020
China [2]

N/A

Previous TB status
Latent TB
COVID-19

−36 confirmed COVID-19 cases
Among which 13 were IGRA+ve
to TB, mean age: 47 years
Case-control study

Liu 2020
China [38]
Case series study of 115
bacterial and 62 other
viral pneumonia.
Controls selected in the
same setting.

Confirmed TB,
COVID-19/TB coN/A
which was defined infection vs COVID-19/no
as a history of or a TB
current diagnosis
of TB.

The matched sample 4510
consisted of COVID-19 patients, of
which 113 had confirmed TB. The
mean age of the total sample was
48.9 years
Longitudinal matched cohort
analysis

Treatments

Karla 2020
Philipines [43]

Comparators

Exposures

Author/Country Population/Study design

Table 2 Description of studies included in review (Continued)
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be higher than the mortality rate of 3.81% for COVID19 worldwide [7]. Three studies [37, 38, 40] reported
COVID-19 recovery time from 9 to 54 days. This is important to highlight that qualitative analysis included
three cases related to SARS-CoV/HIV/TB co-infection
(one case) [31] and COVID-19/HIV/TB co-infection
(two cases) [28–30, 32, 34, 37–41, 44, 45, 47–49].
Among them, SARS-CoV/HIV/TB co-infected case developed mild disease course, one COVID-19/HIV/TB
developed severe COVID-19 and the last case died.
Meta-analysis

We included seven observational studies (six cohort
studies and one case control study) in the meta-analysis
(Fig. 2). A case control and four cohort studies were
conducted in China [38, 41, 44, 45, 48] and two other
cohort studies were undertaken in South Africa [42] and
the Philippines [43] (see Table 2). One cohort included
COVID-19/HIV/TB and COVID-19/TB co-infected
groups were included in the TB occurrence outcome,
with a total sample of 2015 participants. COVID-19 severity included three cohort studies and one case control
for which the total sample size was 2074 participants. A
total of 22,838 and 23,017 participants were included in
recovery and mortality rates respectively. Each of them
included two and three cohort studies respectively. The
results of the meta-analysis based on seven observational
studies including HIV/TB or TB as exposures that may
impact on COVID-19 outcomes were described as
follows:
TB occurrence

This included previous and current TB occurrence
among COVID-19/HIV/TB and COVID-19/TB coinfections. Only one study included TB occurrence [42].
Current TB showed a strong risk of COVID-19 among
HIV-infected cases OR 2.01 (95% CI 1.10–3.66), P = 0.02
compared to uninfected HIV cases OR 1.30 (95% CI
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0.64–2.64), P = 0.47. TB occurrence pooled results between subgroup COVID-19/HIV/TB and COVID-19/TB
was OR 1.67(95%CI 1.06–2.65, P = 0.03). The test for
subgroup differences was not statistically significant with
I2 = 0%, P = 0.36 (Fig. 3).
COVID-19 severity

Three cohort studies [44, 45, 48] and one case control
studies [38] were included to compare mild/moderate
versus severe/critical COVID-19 stages in COVID-19/
TB co-infected patients. The pooled result revealed that
the COVID-19/TB group was at high risk of developing
severe/critical COVID-19 compared to the COVID-19
group OR 4.50 (95%CI 1.12–18.10, P = 0.03). The test of
heterogeneity was not statistically significant P = 0.16,
I2 = 42% (Fig. 4).
Recovery rate

Two cohort studies [42, 43] were included to evaluate
the recovery rate among the COVID-19/HIV/TB group
compared to the COVID-19/TB group. The subgroup
analysis was performed across the two groups. The
COVID-19/HIV/TB subset showed that COVID-19/HIV
co-infected group reached the highest odds in recovery
rate compared to the COVID-19/HIV/TB co-infected
group OR 2.63 (95%CI, 1.80–3.83, P < 0.00001). Similarly, the COVID-19 group had the strongest odds of recovering compared to COVID-19/TB co-infected group
OR 2.09 (95%CI 1.65–2.66, P < 0.00001). The overall result showed that non-TB groups yielded an OR of 2.23
(95%CI 1.83–2.74, P < 0.00001) compared to TB in both
COVID-19/HIV and COVID-19 groups. The test for
subgroup differences was not statistically significant with
P = 0.32 and I2 = 0% (Fig. 5).
Mortality rate

Three observational studies [41–43] compared the mortality rate among COVID-19/HIV/TB and COVID-19/

Fig. 3 Meta-analysis of TB occurrence among COVID-19/HIV/TB or COVID-19/TB co-infections. Outcome: TB occurrence

Tamuzi et al. BMC Infectious Diseases
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Fig. 4 Meta-analysis of COVID-19 severity among COVID-19/TB co-infected patients. Outcome: COVID-19 severity

TB co-infected groups. Subgroup analysis was undertaken to evaluate the heterogeneity between the two
groups. Among those studies, Davies 2020 included both
COVID-19/HIV/TB and COVID-19/TB co-infected
cases. The first subgroup revealed that COVID-19/TB
co-infected group had a 74% risk reduction of dying
compared to the COVID-19/HIVTB co-infected group
(OR 0.36, 95%CI 0.25–0.52, P < 0.00001). In the same
way, the second subgroup analysis including two observational studies showed that the COVID-19 group had a
53% risk reduction of dying compared to the COVID19/TB co-infected group (OR 0.36, 95%CI 0.36–0.60).
The pooled results between non TB and TB in both subgroups revealed OR 0.43, 95%CI 0.35–0.53, P < 0.00001.
The test for subgroup difference showed no significant
heterogeneity across included studies P = 0.26, I2 = 21.1%
(Fig. 6).

Discussion
Reviewing descriptive analysis compared to metaanalysis, meta-analysis illustrated that TB exposure is a
COVID-19 risk factor in point of fact TB occurrence,
COVID-19 severity, and recovery and mortality rates.
However, the descriptive analysis showed the interactions between SARS-CoV, HIV and TB may occur during SARS-CoV or after SARS-CoV. Men are more
vulnerable to SARS or MERS or COVID-19 associated
to HIV/TB or TB. It is highly likely that both previous
SARS-CoV with newly diagnosed PTB acquired active

PTB after contracting SARS. This is so because both had
laboratory-confirmed clinical syndromes associated with
SARS, and both recovered well without anti-TB treatment, with initial biochemical and radiological improvement [29]. The descriptive analysis of cases also found
that SARS-CoV could induce a transient suppression of
cellular immunity that further predisposed patients to
exacerbated reactivation or new TB infection, as is the
case with HIV. SARS-CoV and HIV may decrease conjunctly CD4 count and lymphocytes, adding high corticosteroids [29] as a treatment for SARS-CoV may be TB
precipitant factors [29]. Following this, SARS-CoV or
COVID-19 patients may-be more susceptible to active
and latent TB as proven by different studies [29, 31, 33,
35, 36, 47]. It is important to realize that lung lesions
due to SARS and/or TB may increase significantly the
likelihood of SARS-CoV and TB. Lastly, the descriptive
analysis showed COVID-19 time-to-recovery in COVID19/TB co-infected cases may be longer and severe/critical COVID-19 symptoms may be precocious. An
observational study has showed a statistically significant
result in time-to-recovery (P = 0.0046) [43].
A meta-analysis assessing TB occurrence COVID-19/
HIV/TB versus COVID-19/TB co-infected cases demonstrated that the risk of COVID-19 was high among
current TB/HIV co-infected cases in subgroup analysis.
HIV-infected people are more vulnerable to COVID-19.
Although we estimated the pooled COVID-19 rate and
the result showed that the COVID-19/TB group was at

Fig. 5 Meta-analysis of COVID-19/HIV/TB versus COVID-19/TB co-infections. Outcome: recovery rate

Tamuzi et al. BMC Infectious Diseases

(2020) 20:744

Page 13 of 18

Fig. 6 Meta-analysis of TB mortality among COVID-19/HIV/TB or COVID-19/TB co-infections. Outcome: TB mortality

high risk of developing severe/critical COVID-19 compared to the COVID-19 group. This needs careful interpretation due to a wide overall 95% CI as well as due to
studies with different designs. This evidence is supported
by two large cohort studies conducted in Spain and
South Africa, showing that the risks for PCR-confirmed
COVID-19 diagnosis, hospitalization, Intensive Care
Unit (ICU) admission, and death among HIV-positive
persons receiving ART were greater in men compared to
old age [27, 31, 33, 35, 36, 42, 43]. However, the risk for
hospitalization varied by the nucleoside transcriptase
inhibitor (NRTI) regimen and was lower in patients
receiving TDF/FTC versus those receiving other regimens [27, 31, 33, 35, 36, 42, 43].
Our results suggest that the recovery rates between
COVID-19/HIV/TB
and
COVID-19/TB
groups were quite the same OR 2.63 (95%CI, 1.80–
3.83, P < 0.00001) and OR 2.09 (95%CI 1.65–2.66,
P < 0.00001) respectively. However, COVID-19 patients recovered faster than both COVID-19/HIV/
TB and OR 2.09 (95%CI 1.65–2.66, P < 0.00001).
This observation is supported by qualitative evidence as shown above.
The poor outcome in mortality rate among COVID19/HIV/TB co-infection compared to COVID-19/TB
infection is illustrated in Fig. 6. Both those with
COVID-19/HIV/TB and COVID-19/TB co-infection
had increased mortality risk compared to COVID-19
participants. Given recent developments that have
shown the vulnerability of those ages 18–49 to
COVID-19 [50, 51], younger people living with HIV
(PLWH) may also be at heightened risk for mortality
due to COVID-19 complications. Such risk is predicated on the fact that PLWH under the age of 50
years are both less likely to be diagnosed (and in effect more likely to be immunocompromised) and also
less likely to access and be retained in care, yielding

viral suppression of a mere 37% for those age 25–34
years [51, 52].
Our review had a number of important limitations,
the most important being that almost all included
studies were observational and the number of included studies was limited. Nevertheless, heterogeneity was not statistically significant between studies in
different subgroup analyses and the Egger regression
and Begg and Mazumdar’s test for rank correlation
were not statistically significant with P = 0.684 and
1.00 respectively, showing that publication bias was
minimized.
As shown above, COVID-19/HIV/TB or COVID-19/
TB co-infections are a new medical field that needs
further attention and research in high burden HIV/
TB countries more specifically in sub-Saharan Africa
as the co-existence of those three pandemics may
imply vulnerability to COVID-19 infections and increase TB occurrence. Clear diagnostic algorithms, exploration of drug–drug interactions and clinical
management should be addressed to improve COVID19/HIV/TB outcomes.

Review implications: TB, HIV and COVID-19
diagnostics and clinical management
Even though data are scarce, the analysis indicated
that COVID-19/HIV/TB or COVID-19/TB coinfections may have poor treatment outcomes. This
may be worsened in case TB is not diagnosed and
treated early. Furthermore, COVID-19 can shadow TB
in HIV-infected people or vice versa. For this reason,
we suggest screening for both COVID-19 and TB in
HIV-infected people with COVID-19/TB symptoms
during the COVID-19 pandemic in countries with
high HIV/TB burden. HIV/COVID-19 co-infection requires a simple algorithm and management to boost
TB outcomes.

Tamuzi et al. BMC Infectious Diseases
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TB diagnosis in COVID-19/HIV co-infection

Suspected cases of COVID-19 and TB show similar fever
and/or respiratory symptoms (difficult respiration,
coughing, chest pain, etc.). COVID-19 RT-PCR should
be done in real-time for differential diagnosis of cases
with unknown respiratory syndromes such as PTB [53].
Due to poor outcomes among COVID-19/HIV/TB or
COVID-19/TB co-infections, we recommend COVID-19
real-time RT-PCR should be coupled with Xpert MTB/
RIF assay. In suspected HIV/TB co-infected patients,
Xpert MTB/RIF should be used first rather than traditional microscopy, culture and drug susceptibility testing (DST) [54]. Instead of collecting upper respiratory
tract specimens, lower respiratory tract specimens, such
as sputum, bronchoalveolar lavage, and tracheal aspirates should be collected in suspected COVID-19/HIV/
TB or COVID-19/TB co-infected patients. COVID-19
real-time RT-PCR may last at least 24 h. At the same
time, the Xpert MTB / RIF assay detects M. tuberculosis
and rifampicin resistance within less than two hours
[55]. Xpert MTB/RIF is also a major advance in the
diagnosis of TB, particularly for multidrug-resistant
(MDR) TB and HIV-associated TB [54]. The Xpert
MTB/RIF assay’s sensitivity to detect TB is superior to
that of microscopy and comparable to that of solid culture, along with high specificity [55].
This is important to emphasize that possible causes of
false negative COVID-19 real-time RT-PCR results in
COVID-19/HIV co-infection may be identified in patients on protease inhibitors (PIs) based regimens. We
also recommend systematic TB screening in COVID-19/
HIV co-infection. The adapted algorithms to diagnose
TB in confirmed COVID-19/HIV co-infected adults in
high burden HIV/TB countries are described below:
Option 1: This algorithm includes an interrogatory
about cough of any duration, fever, short breathing, sore
throat, loss of weight, loss of appetite, nausea,
hemoptysis and night sweat. Past medical history includes previously confirmed TB, previous TB contact,
TB preventive therapies, unsuppressed HIV viral load
and CD4 count ≤350 cells/μL. Xpert MTB/RIF assay
should be indicated. If Xpert MTB/RIF assay is positive,
start anti TB drugs.
Option 2: This algorithm includes symptoms and medical history of COVID-19, HIV and TB as described in
option 1. Xpert MTB/RIF assay should be indicated. If
Xpert MTB/RIF assay is negative, the culture associated
with the chest X-ray should be requested. If abnormal
chest X-ray suggestive of TB, start anti-TB drugs, in the
meantime while waiting for culture results.
Option 3: This algorithm includes symptoms and medical history of COVID-19, HIV and TB as described in
option 1. If Xpert MTB/RIF assay is negative and the Xray is not suggestive of TB, the culture associated with
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an approved interferon-gamma release assays (IGRAs)
should be performed. Current evidence indicates that
IGRAs perform similarly to the tuberculin skin test
(TST) at identifying HIV-infected individuals with TB
[56]. However, the decision to use either test should be
based on country guidelines and resource and logistical
considerations. If IGRAs is positive and the culture is
negative, start TB preventive treatment. Isoniazid monotherapy for six (6) months is recommended for the treatment of LTBI in both in high burden HIV/TB countries
[57]. Rifampicin or rifapentine plus isoniazid daily for
three (3) months should be offered as an alternative to
six (6) months of isoniazid. However, rifampicin and
rifapentine should be prescribed with caution in HIV/
COVID-19 co-infection due to potential drug-drug
interactions.
Option 4: This algorithm includes a history of previous
COVID-19, previous contact or active TB, HIV positive,
HIV viral load and CD4 count. All people with cough of
any duration, fever, short breathing, sore throat, weight
loss, hemoptysis, night sweat, arthralgia or myalgia
should be investigated for TB. The Xpert MTB/RIF assay
coupled with COVID-19 IgG/IgM should be indicated.
A recent study has found that the specificities of serum
IgM and IgG to diagnose COVID-19 were both more
than 90% when compared to molecular detection [58]. If
the Xpert MTB/RIF assay is negative, see options 2 and
3.
Clinical management
Drug-drug interactions and clinical considerations

In the case of concurrent HIV and tuberculosis infection
plus SARS-CoV-2 infection, the additional drug might
cause interaction complicating the integrated therapy. In
fact, some pharmaceutical interventions found for
COVID-19 treatment including Protease inhibitors (PIs)
(atazanavir, lopinavir, ritonavir, daranavir, raltegravir,
cobicistat), remdesivir, ribavirin, arbidol, chloroquine,
hydroxychloroquine, methylprednisolone, dexamethasone, anticoagulants and carrimycin may interfere and
interact with TB and/or HIV treatments in multiple
ways. Although protease inhibitors (PIs) were developed
to be selective inhibitors of HIV-1 replication, they have
shown inhibitory activity against a wide variety of pathogens [58], including SARS-CoV. Lopinavir / ritonavir
(LPV/r) has a moderate anti-SARS-CoV-2 antiviral activity which works against the 3CL protease virus [59, 60].
A recent systematic review concluded that it is unclear
whether LPV/r and other ART enhance clinical outcomes in severe symptomatic disease or prevent infection in patients at high- risk of COVID-19 based on the
evidence available [61], as most of the studies included
were case studies and also observational studies were
low of power. Drug-drug interactions between PIs and
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rifampicin are known in HIV/TB co-infection. Studies
have demonstrated that co-administration of PIs with rifampicin reduces PIs systemic concentration to less than
75% (cytochrome P 450 induction) [62, 63]. This may
compromise COVID-19 treatment. Remdesivir should
also not associate to rifampicin in COVID-19/TB coinfection because of strong induction [64]. A recent review has reported that chloroquine phosphate and
hydroxychloroquine showed favorable outcomes in the
recovery of COVID-19 patients [26, 65–68]. Both
chloroquine and hydroxychloroquine are metabolized by
hepatic cytochrome P450 enzyme 2D6 (CYP2D6) [69].
The most frequently involved in drug interactions are
CYP3A4 and CYP2D6 [70]. The reduction in the efficacy
of chloroquine when administered in conjunction with
rifampicin may be due to the inducing effect of rifampicin on multidrug resistance associated protein (MRP)
and development of CYP450 [70]. Additionally, highdose chloroquine is more toxic than lower dose [64].
This is why; studies should clarify chloroquine and
hydroxychloroquine dose adjustment in COVID-19/TB
co-infection. Based on the above, dose adjustments
should be taken into consideration in case PIs, chloroquine, hydroxychloroquine and remdesivir are administered with rifampicin. Another option is to shift
rifampicin to rifabutin or adapted TB regimens without
rifampicin. In contrast, clofazimine used in MDR-TB is
a strong inhibitor of PIs, known substrates [71]. Then,
caution should be taken when administered with PIs.
Another TB drug with in vitro effect used in COVID-19
is carrimycin. Its use in COVID-19 may mitigate active
TB and biases the TB diagnostic.
A study showed an association between corticosteroid
use and lower mortality in COVID-19 patients [68].
Using a glucocorticoid in the early stages of the prognosis for a brief period of time could minimize the inflammation, but longer-term use could result in the risk of
HIV and/or TB activation and even lack of treatment
with TB. Careful use of corticosteroids with low-tomoderate doses in short courses is advised [68]. Besides,
fibrosis and extensive pulmonary pathology secondary to
TB and COVID-19, as defined in the introduction, can
reduce drug penetration at the lung sites. It is a significant risk factor for bad TB outcomes in the event of potential infection or reactivation of TB [72]. This may
also induce MDR-TB or extensively drug-resistant tuberculosis (XDR-TB) or recurrent pneumonia. Then, special
considerations should be taken into account in the clinical management of COVID-19/TB lung fibrosis. Some
RCTs are currently underway evaluating the safety and
effectiveness of antifibrotic therapies on COVID-19 lung
fibrosis [46].
Besides, liver and kidneys toxicities related to severe
and critical COVID-19 need a tailored therapeutic
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approaches in HIV/TB co-morbidities due to some hepatotoxicity and nephrotoxicity of some HIV/TB drugs
such as streptomycin, isoniazid, rifampicin, pyrazinamide, tenofovir disoproxil, atazanavir/ritonavir, lopinavir/ritonavir as well as HIV induced nephropathy and
hepatitis associated to HIV.
Clinical management approach

1. Mild to Moderate COVID-19 associated with HIV/
TB co-infection: Hospitalized in a special unit named
COVID-19/TB units as risk patients. Start COVID-19
antiviral drugs, start or continue anti TB drugs according to the national guidelines and continue ART.
Preferred COVID-19 antivirals are oseltamivir, chloroquine or hydroxychloroquine associated to LV/r or
darunavir/cobicistat and Azithromycin may be indicated [68]. Chloroquine: 1 g PO once on Day 1, then
500 mg PO once daily for 4–7 days, hydroxychloroquine: 800 mg PO once on Day 1, then 400 mg PO
once daily for 4–7 days [64] or lopinavir 400 mg/ritonavir 100 mg PO twice [65]. All of them should be
associated with Azithromycin [64]. Drugs interactions
should be reviewed as described above. Initial evaluation includes a chest x-ray, complete blood count
(CBC), liver transaminases, renal function, inflammatory markers such as C-reactive protein (CRP), Ddimer, and ferritin, while not part of standard care,
may have prognostic value.
2. Severe COVID-19 associated to HIV/TB co-infection:
Hospitalized in COVID-19/TB unit as high-risk patients.
Drug therapy and ventilator support are milestones. Clinicians can refer to COVID-19 antiviral therapy and
immune-based therapy [64]. Start COVID-19 antiviral
drugs as described in mild to moderate COVID-19, add
immune-based therapy, initiate or continue anti TB drugs
according to national guidelines and nephrotoxic ART regimens may be discontinued, switched to another ART regimen or adjusted dose based on the kidney function and
drug-drug interactions [73]. Remdesivir is recommended in
severe/critical COVID-19 however this cannot be administered with rifampicin [64]. Short period low-dose corticosteroid therapy is preferred over no corticosteroid therapy
in HIV/TB co-infection and also the patients are in the intensive care unit [64]. Anticoagulant therapy mainly with
low molecular weight heparin should be initiated early as
this appears to be associated with better prognosis in severe
COVID-19 patients [74]. Ventilator support, oxygen
through a face mask and symptomatic therapy should be
indicated. Initial evaluation includes chest x-ray/CT-scan
and CBC should be indicated. Liver transaminases and
renal function should be monitored regularly in consideration of COVID-19/HIV/TB drug-drug interactions and
clinical considerations. Measurements of inflammatory
markers, D-dimer, and ferritin are part of the management.
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3. Critical COVID-19 associated to HIV/TB coinfection: Hospitalized in COVID-19/TB unit with ICU
as high-risk patients. Infection control and testing, ventilator support, hemodynamic, and drug therapy are milestones [65]. Apply COVID-19, TB and HIV management
as described in severe COVID-19. Short period low-dose
corticosteroid therapy, anticoagulant therapy and norepinephrine as the first-choice vasopressor are recommended [64]. Anticoagulant therapy mainly with low
molecular weight heparin appears to be associated with
better prognosis in severe/critical COVID-19 patients
with markedly elevated D-dimer [74]. There is strong
evidence against the use of hydroxyethyl starches for the
acute reanimation of adults with COVID-19 in shock
[75]. In adults with COVID-19 in shock, if the peripheral
oxygen saturation (SpO2) is < 92%, the review suggested
starting supplemental oxygen if SpO2 is < 90% [75]. Initial evaluation includes chest x-ray/CT-scan and CBC
should be indicated. Liver transaminases and renal function should be monitored regularly in consideration of
COVID-19-HIV and TB drug-drug interactions and clinical considerations. Inflammatory markers, D-dimer, cardiac enzymes and ferritin monitoring should be part of
the management.
4. Previous history of COVID-19 in HIV/TB coinfection: This group of cases should be treated as HIV/
TB co-infection as described in different national guidelines. Therefore, emphasis should be put on the risk of
severe lung fibrosis that may induce MDR-TB or XDRTB. Ongoing trials are evaluating the safety and effectiveness of antifibrotic therapy in COVID-19 severe and
critical patients [46]. This could be beneficial in COVID19-HIV and TB co-infected cases due to their synergic
roles in inducing pulmonary fibrosis.

Conclusion
This is the first systematic review of the burden of
COVID-19-HIV and TB co-infection in high burden
HIV/TB countries. This review highlighted special considerations that should be taken in high burden HIV and
TB countries at present and in the future. The results of
the present descriptive analysis and meta-analysis of
twenty one studies among which two were four case reports, eight case series, one case-control and eight cohort studies. Descriptive analysis has shown that SARSCoV, MERS-CoV and COVID-19 associated with HIV/
TB or TB are more common in males and the time-torecovery is long compared to the non-exposure groups.
Meta-analysis suggests that HIV/TB co-infection or TB
exposures increase the risk of severe/critical COVID-19
and the mortality. The current TB group has an increased risk of COVID-19 compared to the previous TB.
Additionally, the HIV/TB co-infected group has the
highest risk in the COVID-19 mortality rate and poor
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recovery rate. This evidence is strong enough as substantial heterogeneities were absent in all the results (I2
values were less than 50% in all the meta-analysis).
Based on the results, the review offers special attention
on diagnostics and management of COVID-19/HIV/TB
and COVID-19/TB co-infections. TB diagnostic suggests
four algorithms fast-tracking TB investigations in
COVID-19/HIV/TB and COVID-19/TB co-infections.
Well-structured clinical management has been suggested, focusing on COVID-19, HIV and TB drug-drug
interactions and also COVID-19 clinical considerations.
Knowing that COVID-19 and TB may induce the development of severe lung disease leading to pulmonary
fibrosis in the future, further studies are needed with cohorts of HIV/COVID-19 co-infected individuals. More
research is needed to explore the effect of lung fibrosis
related to COVID-19 in high burden HIV/TB countries.
This pressing priority will shed light on the utility of
prophylaxis treatments in preventing post-COVID-19
related LRTIs in high burden HIV/TB countries.
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